

“ORBITAL PSEUDOTUMOR”

University of Naples
“Federico II”

What's Orbital Pseudotumor?



Terminology:

- Orbital Pseudotumor: Birc-Hirschfeld 1905
- Cellulitis Fibroplastica: Verebely 1926
- Orbital Granuloma: Reese
- Non specific Orbital Granuloma: Easton-Smith
- Orbital Lipogranuloma: Coop
- Inflammatory non neoplastic Orbital Pseudotumor: Hogan-Zimmerman
- **Idiopathic** inflammatory Orbital Pseudotumor: Jakobiec
- Lymphocytic inflammatory Orbital Pseudotumor >>>>
Non vasculitic inflammatory Orbital Tumor: Henderson
- **Non Specific** Orbital Inflammation: Rootman




Hystologic Pattern

- **ORGAN:** eyelid, extraocular muscle, sclera, lacrimal gland....connective tessue
- **TYPE OF CELLS:** miscellaneous lymphocytic, plasma cells, fibroblasts.
- **DISTRIBUTION:** lymphoid follicle, perivascular, fibrous scarring,

Histologic Pictures:

lymphoid, granulomatous and sclerosing



“Orbital pseudotumor”

- **Inflammatory-Non Neoplastic:** with exclusions of reactive lymphoid hyperplasia, benign pseudolymphoma (true benign low grade lymphoma)
- **Idiopathic**
- **Non Specific:** with exclusions Syphilis, Tuberculosis, Graves ophthalmopathy, Wegener granulomatosis, Polyarteritis nodosa, Sarcoidosis, Amyloidosis, Foreign body, infection Cellulitis, Hemangioma, rupture Dermoid cyst.
- **Idiopathic Non-specific Orbital Inflammation (INOI)**




Questions ?

- Are **myositis, dacrioadenitis, tenonitis** etc.. to be considered as part of the whole group of INOI or they have its own **clinical identity**?
- Is INOI a **systemic** or a **local inflammatory disease localized just to the Orbit?** (like low grade lymphoma or chronic infections)

PROJECTS

- Retrospective non-comparative case series on Management of Orbital Pseudotumor
- Prospective pilot study on possible Etiologic role of Chlamydia and Mycoplasma infections in Orbital Pseudotumor

Management of INOI



Methods

- We retrospectively analyzed 250 pz files with presumed diagnosis of INOI from 1976 to 2002
- We reviewed and recorded onto a data base: age, signs and symptoms, visual acuity, systemic diseases at presentation, diseases developed during follow up, imaging tests (MRI, CT, Ultrasound), diagnose, therapy (medical, surgical, both), recurrences, interval time therapy-recurrences, hystological diagnose of recurrences.

Methods

- After re-evaluations of 250 pz. files only **120** with true INOI with adequate follow up were included in the study. Pz who developed lymphoma or other systemic or local diseases different from INOI were excluded. (lymphoma, Graves ophthalmopathy, meningioma, schwannoma)
- Based on radiological and histological ground we **classified diagnosis** according to the orbital structure primarily affected: **myositis** (Myo), **orbital mass** (Ps), **dacrioadenitis** (dacrio), **tenonitis**, **periostitis** and **Tolosa Hunt syndrome**.

Methods



- **Investigations:**
- t3-t4, TRH, TSH, Thyroid-Abs were performed in pz with enlargement of extraocular muscles in order to exclude Graves Ophthalmopathy
- anti-nuclear Ab (ANA), antineutrophil-cytoplasmic Ab (ANCA), angiotensin-converting enzyme (ACE), erithrocyte sedimentation rate (ESR), Reumatoid F. circulating immune ocomplexes.

Methods

- **Open orbital biopsy** were performed on 51(42%) of pz while pz with pain ophthalmoplegia and radiologic absence of infiltration (Tolosa Hunt syndrome) and those who did not receive histologic examination the diagnosis of INOI was supported by combined clinical findings, radiological incontrovertible appearance of infiltration and long term **follow up (mean 13 years)**

Methods

- None of pz had received treatment before
- Treatment criteria was based empirically on the ammount of inflammation and on clinical and radiological appearance, regardless of discriminating on the base of single structure envolved in the orbit
- **Medical (MT)**: 1-1,5 mg/kg prednisolon in 65(54%) of pz
- **Surgical (ST)**: debulking in 29(24%) of pz
- **Steroids+Surgical (MST)**: in 22(18%) of pz
- 12/26 pz who **recurred** (47%) underwent open orbital biopsy in order to exclude diagnosis different from INOI even though already had ST as first therapeutic approach

Results

- Mean age: 42 years (ranged between 5-84)
- Bilateral cases were not observed
- 63/120 pz (52%) mass located in a variable infiltrated manner
- 25 pz (20%) lacrimal gland involvement
- 23 pz (19%) myositis
- 2 pz (1%) tenonitis
- 5 pz (4%) periostitis
- 2 pz (1%) Tolosa Hunt syndrome

Symptoms

| | Freq. | % | % valid. | % add. |
|------------|-------|-------------|----------|--------|
| None | 44 | <u>36,7</u> | 36,7 | 36,7 |
| Pain | 35 | 29,2 | 29,2 | 65,8 |
| Diplopia | 22 | 18,3 | 18,3 | 84,2 |
| Dip + pain | 19 | 15,8 | 15,8 | 100,0 |
| Total | 120 | 100,0 | 100,0 | |

Signs

| | <u>Freq.</u> | <u>%</u> | <u>% valid.</u> | <u>% add.</u> |
|------------------------|--------------|-------------|-----------------|---------------|
| None | 10 | 8,3 | 8,3 | 8,3 |
| Exophthalm | 41 | <u>34,2</u> | 34,2 | 42,5 |
| Ptosis | 10 | 8,3 | 8,3 | 50,8 |
| Exophthalm + ptosis | 25 | 20,8 | 20,8 | 71,7 |
| Edema | 24 | 20,0 | 20,0 | 91,7 |
| Retraction | 1 | 8 | 8 | 92,5 |
| s-shaped | 1 | 8 | 8 | 93,3 |
| Exophthalm + edema | 2 | 1,7 | 1,7 | 95,0 |
| edema + ptosis | 6 | 5,0 | 5,0 | 100,0 |
| Total | 120 | 100,0 | 100,0 | |

Therapies

| | <u>Freq.</u> | <u>%</u> | % valid. | % add. |
|------------|--------------|----------|----------|--------|
| No therapy | 4 | 3,3 | 3,3 | 3,3 |
| ST | 29 | 24,2 | 24,2 | 27,5 |
| MST | 22 | 18,3 | 18,3 | 45,8 |
| MT | 65 | 54,2 | 54,2 | 100,0 |
| Total | <u>120</u> | 100,0 | 100,0 | |

Recurrences

| | | TREAT. | | | | Total |
|--------|-----------------|---------------|-----------|------------|-----------|------------|
| | | No therapy | <u>ST</u> | <u>MST</u> | <u>MT</u> | |
| RECUR: | Negative | 4 | 23 | 17 | 50 | 94 |
| | <u>Positive</u> | | 6 | 5 | 15 | <u>26</u> |
| Total | | 4 | 29 | 22 | 65 | <u>120</u> |

Recurrences-Treatments (M&S)

| | Valore | df | Sig. asint. (2 vie) | Sig. esatta (2 vie) | Sig. esatta (1 via) |
|------------------|--------|----|------------------------|------------------------|------------------------|
| K-Pearson | ,066 | 1 | ,797 | | |
| Correction | ,000 | 1 | 1,000 | | |
| Fisher T. | | | | 1,000 | ,512 |
| Asso. | ,065 | 1 | ,799 | | |
| N. | 94 | | | | |

Histopathology of pz recurred:

| | Freq. | % | % valid. | % add. |
|------------------|-----------|-------|----------|--------|
| None | 14 | 53,8 | 53,8 | 53,8 |
| Ps | 2 | 7,7 | 7,7 | 61,5 |
| dacrio | 2 | 7,7 | 7,7 | 69,2 |
| Ps sclerosis | 7 | 26,9 | 26,9 | 96,2 |
| Ps eosinophil | 1 | 3,8 | 3,8 | 100,0 |
| Total | <u>26</u> | 100,0 | 100,0 | |


Times disease-recurrence (years)

| | N. | <u>Media</u> | D.S. | Error std. | Interv. Conf. 95% Lim. | Lim. | Min | Max |
|--------------|-----|--------------|------|---------------|---------------------------------|------|-----|-----|
| No therap | 4 | ,00 | ,00 | ,00 | ,00 | ,00 | 0 | 0 |
| ST | 29 | ,55 | 1,72 | ,32 | -,10 | 1,21 | 0 | 9 |
| MST | 22 | <u>1,05</u> | 3,26 | ,69 | -,40 | 2,49 | 0 | 15 |
| MT | 65 | ,74 | 2,06 | ,26 | ,23 | 1,25 | 0 | 10 |
| Total | 120 | ,73 | 2,21 | ,20 | ,33 | 1,12 | 0 | 15 |

Multiple analysis (Bonferroni): Therapies/recurrences

| (I) TREATT | (J) TREATT | Diff. medie (I- J) | Error std. | <u>Sig.</u> | Interval conf. 95% Limit | Limit |
|---------------|---------------|--------------------------|------------|-------------|--------------------------------|-------|
| no therapy | ST | -,55 | 1,19 | 1,000 | -3,74 | 2,64 |
| | MST | -1,05 | 1,21 | 1,000 | -4,30 | 2,21 |
| | MT | -,74 | 1,15 | 1,000 | -3,82 | 2,34 |
| ST | no therapy | ,55 | 1,19 | 1,000 | -2,64 | 3,74 |
| | MST | -,49 | ,63 | 1,000 | -2,19 | 1,20 |
| | MT | -,19 | ,50 | 1,000 | -1,52 | 1,15 |
| MST | no therapy | 1,05 | 1,21 | 1,000 | -2,21 | 4,30 |
| | ST | ,49 | ,63 | 1,000 | -1,20 | 2,19 |
| | MT | ,31 | ,55 | 1,000 | -1,17 | 1,78 |
| MT | no therapy | ,74 | 1,15 | 1,000 | -2,34 | 3,82 |
| | ST | ,19 | ,50 | 1,000 | -1,15 | 1,52 |
| | MST | -,31 | ,55 | 1,000 | -1,78 | 1,17 |

Scleritis and Choroidal folds



Conclusion

Is INOI a local or a systemic disease?

- Since systemic diseases are by definition characterized by a multisystemic involvement it appears controversial consider the INOI a systemic disease limited just to the orbit; in our study the absence of any other systemic sign or other localization on long term follow-up (mean 13 years) corroborate the hypothesis that **INOI** is a local disease

Conclusion

Are **myositis, dacrioadenitis, tenonitis etc..** to be considered as part of the whole group of INOI or they have its own **clinical identity?**

- we demonstrate they should be considered all together as **single** disease because of shearing the unknown aethiology and the same clinical, therapeutic and prognostic course irrespective of their original tessue location

Ethiologic role of Chlamydia and Mycoplasma infections in INOI

Questions ?

- Are myositis, dacrioadenitis, tenonitis etc.. to be considered as part of the whole group of INOI or they have its own clinical identity?
- Is INOI a systemic or a local inflammatory disease localized just to the Orbit? (like low grade lymphoma or chronic infections)

Scientific evidence:

- inflammatory pseudotumor of the lung manifested as a mediastinal mass can be associated with Mycoplasma pn. infection: Kim et al. Pediatr Radiol 1992
- fluorescence with monoclonal Abs against the major outer membrane proteins of Chlamydia species have been found in patients with spindle-cell nodule of the urinary bladder (inflammatory pseudotumor): Lo JW et al. Diagn Cytopathol 1992

Scientific evidence:

- Rectal pseudotumor due to *Chlamidia tracomatis* in a male homosexual. Ruther U. at all.: Endoscopy 1990
- Pseudotumor of the orbit and retroperitoneal fibrosis. A form of multifocal fibrosclerosis. Richards AB at all. Arch.Ophthalmol 1980

Methods

- We analyzed 8 pz (3M and 5F) with clinical presentations (signs and symptoms), imaging study (MRI, CT scan and echography) and histological result compatible with INOI.
- All patients underwent a complete laboratory investigations and imaging analysis in order to exclude local and systemic disease of known aetiology

Methods

- Specifically serum t3 –t4, thyrotropin releasing hormone, thyroid antibodies and thyroid stimulating hormone levels was performed in patients with primarily muscles involvement in order to exclude Graves Ophthalmopathy.
- anti-nuclear antibodies, antineutrophil-cytoplasmic auto-antibodies, angiotensin-converting enzyme, erythrocyte sedimentation rate, rheumatoid factor and circulating immune complexes were also tested to exclude sarcoidosis, Wegner's granulomatosis, autoimmune and infectious diseases

Methods

- All patients underwent a surgical approach (debulking) with open orbital biopsy
- All tissue biopsy specimens were fixed in 4% formalin and embedded in paraffin for conventional histological staining (hematoxylin&eosin, Giemsa and periodic a acid-Schiff).
- Immunologic studies were performed on each fresh tissue specimen, which was storage at -80°C and frozen sections were prepared for the immunofluorescence tests.

Methods

- On histological samples: to detect Chlamydia at all stages of its development cycle (elementary bodies, reticulate bodies and inclusion bodies) direct fluorescent Ab technique (Chlamydia direct IF: bio-Mérieux) was used
- On the blood samples immunoenzymatic ELISA test (Eurospital Ct, Cp) was used to detect respectively Ig A and Ig G Ab against Ch. trachomatis and Ig.M and Ig.G Ab against Ch. Pneumonia; immunoenzymatic ELISA test (Eurospital Myp) was used to detect Ig M and Ig G Ab against Mycoplasma.

Results

- On histological examination: lesions were all classified as chronic non specific inflammations
- On immunofluorescence: the histological sections fail to show monoclonal antibody staining pattern against Chlamydia species in all cases
- On blood samples: none of autoantibodies against Chlamydia and Mycoplasma species were detected in the serum of patients involved in the study.

Conclusions

- if we consider that 40% and 50% of normal population are blood positive for anti-Mycoplasma antibody and anti-Chlamydia pneumonia respectively, the total negativity of our patients do not support our hypothesis that orbital pseudotumor could be do to infection.
- Similarly at immunofluorescence test we were not able to show Chlamydia trachomatis or pneumonia inclusions on frozen sections which also do not corroborate our assumption

Guidelines

- **Mainstay of therapy in INOI:** never-ever use steroids as first line of treatment if you suspect INOI (NSAD) apart from Myositis and Tolosa-Hunt S. characterized by 24h dramatic pain and motility deficiency in absence of infiltration (use of steroids is unjustified-confusing-dangerous and nowadays negligent on medical legal base)
- If you suspect **orbital cellulitis** in a little child starting intravenous antibiotics is imperative